Fate Therapeutics, Inc. (FATE)
1.28
-0.06
(-4.48%)
USD |
NASDAQ |
Nov 13, 16:00
1.275
0.00 (0.00%)
After-Hours: 19:59
Fate Therapeutics Shareholders Equity (Quarterly) : 133.03M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 133.03M |
| June 30, 2026 | 153.44M |
| March 31, 2026 | 179.71M |
| December 31, 2025 | 207.18M |
| September 30, 2025 | 234.07M |
| June 30, 2025 | 261.36M |
| March 31, 2025 | 288.41M |
| December 31, 2024 | 318.73M |
| September 30, 2024 | 362.33M |
| June 30, 2024 | 396.98M |
| March 31, 2024 | 426.12M |
| December 31, 2023 | 368.42M |
| September 30, 2023 | 402.78M |
| June 30, 2023 | 437.76M |
| March 31, 2023 | 477.47M |
| December 31, 2022 | 483.94M |
| September 30, 2022 | 518.00M |
| June 30, 2022 | 580.48M |
| March 31, 2022 | 633.39M |
| December 31, 2021 | 678.84M |
| September 30, 2021 | 730.33M |
| June 30, 2021 | 752.07M |
| March 31, 2021 | 790.10M |
| December 31, 2020 | 384.44M |
| September 30, 2020 | 424.36M |
| Date | Value |
|---|---|
| June 30, 2020 | 474.11M |
| March 31, 2020 | 219.22M |
| December 31, 2019 | 244.76M |
| September 30, 2019 | 268.04M |
| June 30, 2019 | 127.53M |
| March 31, 2019 | 145.84M |
| December 31, 2018 | 160.47M |
| September 30, 2018 | 173.93M |
| June 30, 2018 | 51.82M |
| March 31, 2018 | 65.00M |
| December 31, 2017 | 77.19M |
| September 30, 2017 | 45.75M |
| June 30, 2017 | 55.21M |
| March 31, 2017 | 63.86M |
| December 31, 2016 | 73.15M |
| September 30, 2016 | 25.37M |
| June 30, 2016 | 23.13M |
| March 31, 2016 | 30.73M |
| December 31, 2015 | 38.04M |
| September 30, 2015 | 45.00M |
| June 30, 2015 | 51.07M |
| March 31, 2015 | 21.25M |
| December 31, 2014 | 28.34M |
| September 30, 2014 | 33.58M |
| June 30, 2014 | 39.64M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| AVITA Medical, Inc. | -31.04M |
| Agenus, Inc. | -105.37M |
| Amgen, Inc. | 14.35B |
| Anika Therapeutics, Inc. | 137.58M |
| BioCryst Pharmaceuticals, Inc. | -397.38M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 238.28M |
| Total Liabilities (Quarterly) | 105.24M |
| Debt to Equity Ratio | 0.56 |
| Current Ratio | 4.413 |
| Net Debt Paydown Yield | 0.47% |